Until the past 4 years, no treatment option existed for patients with refractory differentiated thyroid cancer, who were treated routinely with supportive care. The first drug to be approved for these patients by the FDA was sorafenib in 2013, followed by lenvatinib in 2015 —

中文翻译：

---

靶向治疗：Lenvatinib SELECTs生存获益

直到过去4年，对于顽固性分化型甲状腺癌的患者，尚无治疗选择，这些患者常规接受支持治疗。FDA在2013年批准了针对这些患者的首个药物，索拉非尼在2013年，随后在2015年出现了lenvatinib —